Search clinical trials for: Immediate Release Sublingual Buprenorphine

Total 309 results

Royal Victoria Hospital, Canada

Not yet recruiting

Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (STOPIT)

Moderate to Severe Opioid Use Disorder

Canada
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Suspended

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

Opioid-use Disorder

United States
Friends Research Institute, Inc.

Not yet recruiting

Buprenorphine for Individuals in Jail

Opioid Use Disorder

United States
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
NYU Langone Health
National Institute on Drug Abuse (NIDA)

Not yet recruiting

Assessing Optimal XRB Initiation Points in Jail

Opioid Use Disorder

United States
Heptares Therapeutics Limited
Quotient Clinical

Completed

Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation

Alzheimer's Disease

United Kingdom
GlaxoSmithKline
Quotient Clinical

Completed

A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses

Autoimmune Diseases

United Kingdom
GlaxoSmithKline
Quotient Sciences

Completed

A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772

Autoimmune Diseases

United Kingdom
NYU Langone Health
NYC Health + Hospitals

Completed

XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept

Opioid Dependence

United States
Titan Pharmaceuticals

Completed

A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants (PRO-814)

Opioid Dependence
Pfizer

Completed

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Healthy

Belgium
Yih-Ing Hser
National Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaborators

Not yet recruiting

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (RXR)

Substance-Related Disorders | Opioid-Related Disorders | Narcotic-Related Disorders

United States
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Psychiatric University Hospital, Zurich

Unknown

Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches

Heroin Addiction

Switzerland
University of Chicago

Completed

The Effects of Buprenorphine on Responses to Verbal Tasks

Basic Science

United States
NYU Langone Health
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)

Opioid Use Disorder (OUD)

United States
INSYS Therapeutics Inc

Completed

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

Opiate Dependence

United States
Vanderbilt University Medical Center
National Institute on Drug Abuse (NIDA)

Recruiting

Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia

Pain | Analgesia | Abuse Opioids

United States
Orexo AB
Worldwide Clinical Trials

Completed

Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence

Opioid Dependence, on Agonist Therapy

United States
GlaxoSmithKline

Completed

A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects

Diabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus

United States
Indivior Inc.

Completed

Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population

Opioid Dependence

United States
Pfizer

Completed

A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961

Healthy Subjects

United States
Wayne State University

Completed

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence (BOS)

Heroin Dependence | Opioid Use Disorder

United States
GlaxoSmithKline

Completed

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Diabetes Mellitus, Type 2

United States
Johns Hopkins University

Completed

Assessing the Safety of Buprenorphine in People With Sickle Cell Disease

Sickle Cell Disease

United States
Orexo AB
Worldwide Clinical Trials

Completed

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults (ISTART)

Opioid Dependence, on Agonist Therapy

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study (MOMs-INO)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Neonatal Opiate Withdrawal Syndrome | Drug Abuse in Pregnancy

United States
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
Alar Pharmaceuticals Inc.

Completed

Single Ascending Dose Study of ALA-1000

Opioid-use Disorder

United States
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Indivior Inc.

Completed

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder | Opioid-related Disorders

United States
ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
T. John Winhusen, PhD
National Institute on Drug Abuse (NIDA); The Emmes Company, LLC

Active, not recruiting

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study (MOMs-CMA)

Pregnancy Related | Opioid-Related Disorders | Substance Abuse | Drug Abuse | Drug Addiction | Neonatal Abstinence Syndrome | Drug Abuse in Pregnancy | Neonatal Opioid Withdrawal Syndrome

United States
Pfizer
ViiV Healthcare

Completed

Study to Estimate the Pharmacokinetics, Bioavailability and Effect of Food on Single Dose Modified-release Lersivirine 500 mg in Healthy Subjects

Healthy Volunteer

Belgium
Orexo AB
Worldwide Clinical Trials

Completed

Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence

Opioid-Related Disorders | Opiate Dependence

United States
Titan Pharmaceuticals

Terminated

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence (PRO-810)

Opioid Dependence

United States
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Back Pain Lower Back Chronic

United States
Indivior Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder

Opioid Use Disorder

United States
VA Office of Research and Development

Recruiting

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder (VA-BRAVE)

Opioid Use Disorder

United States
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Purdue Pharma LP

Terminated

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

Osteoarthritis

United States
Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA); Baltimore City Health Department

Enrolling by invitation

Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine (OUTLAST-B)

Opioid-use Disorder

United States
University of Vermont

Unknown

Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation

Opioid-use Disorder

United States
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
Yale University
Harvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaborators

Recruiting

Emergency Department-Initiated Buprenorphine Validation Network Trial

Opioid-use Disorder

United States
Indivior Inc.
Reckitt Benckiser LLC

Completed

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

Opioid Dependency
Sarfez Pharmaceuticals, Inc.

Recruiting

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Heart Failure | Overactive Bladder | Incontinence

United States
GlaxoSmithKline

Completed

Healthy Volunteer Study Using 3 Different Formulations of Firategrast

Multiple Sclerosis, Relapsing-Remitting

Australia
KalVista Pharmaceuticals, Ltd.

Completed

Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations

Hereditary Angioedema

United Kingdom
Indivior Inc.

Completed

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Opioid Dependence | Opioid Related Disorders

United States

3

Subscribe